Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C16H16F3NO |
| Molecular Weight | 295.2995 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2
InChI
InChIKey=WIQRCHMSJFFONW-UHFFFAOYSA-N
InChI=1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2
DescriptionCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27890559 | https://www.ncbi.nlm.nih.gov/pubmed/1415832 | https://www.ncbi.nlm.nih.gov/pubmed/15678084 | https://www.ncbi.nlm.nih.gov/pubmed/19014888
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/27890559 | https://www.ncbi.nlm.nih.gov/pubmed/1415832 | https://www.ncbi.nlm.nih.gov/pubmed/15678084 | https://www.ncbi.nlm.nih.gov/pubmed/19014888
Norfluoxetine is an active N-desmethyl metabolite of the antidepressant fluoxetine that inhibits serotonin uptake. Norfluoxetine is selective serotonin reuptake inhibitor (SSRI) but little is known about its pharmacological actions. Seproxetine (S- Norfluoxetine) was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Determination of fluoxetine and norfluoxetine in human plasma by high-pressure liquid chromatography with fluorescence detection. | 1998 Oct |
|
| Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. | 2000 Dec 5 |
|
| Effect of alosetron on the pharmacokinetics of fluoxetine. | 2001 Apr |
|
| Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. | 2001 Aug |
|
| Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. | 2001 Sep |
|
| Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction. | 2008 Mar |
Patents
Sample Use Guides
Rat cortical membranes equivalent to 50 mkg of protein were incubated at 37°C for 30 minutes in 2 ml of reaction medium containing the Norfluoxetine (1-1000nM), 0.1 nM [3Hlparoxetine, 50 mmol/L Tris-HG, pH 7.4, 150 mmol/L NaG, and 5 mmol/L KCl. Fluoxetine at 1 mkM/kg was used to determine nonspecific binding
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C036139
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY | |||
|
K8D70XE2F4
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY | |||
|
Norfluoxetine
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY | |||
|
83891-03-6
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY | |||
|
SUB32375
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY | |||
|
DTXSID80866540
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY | |||
|
100000124308
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY | |||
|
4541
Created by
admin on Sat Dec 16 06:50:20 GMT 2023 , Edited by admin on Sat Dec 16 06:50:20 GMT 2023
|
PRIMARY |
PARENT (METABOLITE ACTIVE)
SUBSTANCE RECORD
